MASH

e-therapeutics plc shares now trading on JP Jenkins

Retrieved on: 
Venerdì, Maggio 10, 2024
RNA interference, Commercial, AIM, ETX, Galapagos NV, Automation, Appointment, Novo Nordisk, Companies House, Biology, Drug development, Drug discovery, Therapy, MASH, Pharmaceutical industry

JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis.

Key Points: 
  • JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis.
  • JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).
  • The indicative pricing for the ordinary shares (ISIN: GB00B2823H99), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/e-therapeutics-plc/).
  • Veronika Oswald, Commercial Director of JP Jenkins said: “ETX’s transition from AIM to the JP Jenkins venue marks a pivotal milestone in our mission to enhance accessibility and liquidity for their shareholders and investors.

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Genetics, Liver disease, Coronary artery disease, Research, N-Acetylgalactosamine, Weight loss, Doctor of Philosophy, Webcast, SVP, DSM-IV codes, CSO, Biomarker, Drug discovery, AATD, RNA editing, Activin and inhibin, Facial muscles, Pharmacokinetics, LNP, SAD, GSK, Serum, Duchenne muscular dystrophy, HTT, Cerebrospinal fluid, MASH, Weight, Safety, Health, RNA, Obesity, Human, Therapy, HD, Central nervous system, Clinical trial, ED50, Small RNA, Stanford University, Lof, Genomics, Exon, Science, Senior, Patient, Cardiovascular disease, MBA, PD, Lipolysis, Q&A, Pharmaceutical industry

ET today

Key Points: 
  • ET today
    CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • Revenue was $12.5 million for the first quarter of 2024, as compared to $12.9 million in the first quarter of 2023.
  • Net loss was $31.6 million for the first quarter of 2024, as compared to $27.4 million for the first quarter of 2023.
  • ET to review the first quarter 2024 financial results and pipeline updates.

Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

Retrieved on: 
Giovedì, Maggio 9, 2024
Stanford University, Genetics, Genomics, RNA editing, University of Oxford, Molecular epidemiology, Health, Gene editing, RNA, Doctor of Philosophy, Computational biology, Research, Employment, Obesity, Therapy, Senior, SVP, GSK, Patient, DSM-IV codes, Faculty, Cardiovascular disease, Karolinska Institute, MBA, Biology, Framingham Heart Study, RSU, Drug discovery, MASH, Insulin resistance, Pharmaceutical industry

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer.

Key Points: 
  • CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer.
  • Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK.
  • Dr. Ingelsson brings to Wave deep expertise in genetics and drug discovery, as well as substantial experience in metabolic diseases.
  • He will leverage his experience to accelerate identification of new genetic insights and rapidly translate those insights into RNA medicines at Wave, including with our wholly owned INHBE program for obesity,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Giovedì, Maggio 9, 2024
Semaglutide, Person, News, Complaint, Guggenheim Partners, Weight loss, Partnership, P.C, Obesity, NASH, District court, Defendant, Court, Bloomberg, Hepatology, Kerrisdale, Telephone, MASH, Pharmaceutical industry

Investors have until July 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until July 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
  • The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis ("MASH").
  • On November 30, 2023, Altimmune announced topline results from its 48-week MOMENTUM Phase 2 trial evaluating pemvidutide for the treatment of obesity (the "MOMENTUM Trial").

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 9, 2024
MASH, University, Patient, Cirrhosis, Research and development, Liver disease, EASL, Safety, Hypertriglyceridemia, Administration, Journal of Clinical Pathology, Hepatology, Virginia Commonwealth University, PRIME, European Medicines Agency, Liver, Enrollment, EMA, Fibrosis, Division, SAN, Pharmaceutical industry

SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the first quarter ended March 31, 2024.
  • These key clinical developments, coupled with our agreement for commercial supply, are designed to strategically enhance our readiness for potential commercialization."
  • ENLIGHTEN-Cirrhosis, the second trial in the program, is planned to evaluate patients with compensated cirrhosis and is expected to initiate in the second quarter of 2024.
  • As of March 31, 2024, 89bio had cash, cash equivalents and marketable securities of approximately $562.3 million.

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

Retrieved on: 
Martedì, Maggio 7, 2024
University, FASN, EASL, Hepatology, F2, Patient, Fibrosis, SAN, Division, MASH

SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced a General Session oral presentation of denifanstat Phase 2b FASCINATE-2 study data in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the European Association for the Study of the Liver (EASL) International Liver Congress 2024 held in Milan, Italy from June 5-8, 2024.

Key Points: 
  • SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced a General Session oral presentation of denifanstat Phase 2b FASCINATE-2 study data in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the European Association for the Study of the Liver (EASL) International Liver Congress 2024 held in Milan, Italy from June 5-8, 2024.
  • General Session Oral Presentation Title: Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week international, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis.
  • Presenter: Rohit Loomba M.D., MHSc, ASLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California San Diego, La Jolla, United States

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Retrieved on: 
Giovedì, Maggio 9, 2024
Health, FDA, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, Phase, Inflammation, Food, Diabetes, Liver disease, A3, Disease, Obesity, NASH, Investigational New Drug, Fatty liver disease, Cirrhosis, Patient, Fibrosis, CANF, MASH, Pharmaceutical industry

This potentially makes Namodenoson an ideal specific candidate for the treatment of MASH.

Key Points: 
  • This potentially makes Namodenoson an ideal specific candidate for the treatment of MASH.
  • Indeed, in a Phase IIa clinical study Namodenoson, has been shown to reduce hepatic steatosis, inflammation and fibrosis, with an excellent safety profile.
  • Currently Can-Fite is enrolling patients for a Phase IIb clinical study in Europe and in Israel and the IND approval by FDA will allow for the recruitment of patients in the US.
  • The Phase IIb trial is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed MASH.

Cellarity Appoints Head of Platform to Advance Vision for Novel Drug Creation

Retrieved on: 
Martedì, Maggio 7, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Health Technology, Sickle cell disease, University, Flagship Pioneering, SCD, Machine learning, Life, IND, Novo Nordisk, Chemistry, Biology, Pharming, Multimedia, Drug development, Genomics, Drug discovery, MASH, Head, Pharmaceutical industry

In this role, Woelk will lead Cellarity’s revolutionary platform to create drugs that are presently out of reach with traditional methods of drug discovery.

Key Points: 
  • In this role, Woelk will lead Cellarity’s revolutionary platform to create drugs that are presently out of reach with traditional methods of drug discovery.
  • The Cellarity platform uses proprietary AI models to link biology and chemistry with high-dimensional multi-omic data to uncover novel actionable insights into disease biology and create non-intuitive drug candidates in a vast array of clinical conditions.
  • “Topher’s experience is particularly relevant to Cellarity as we continue to invest in our platform.
  • “I look forward to helping advance the platform by bringing to life insights that will open up opportunities for new drug development programs and help accelerate the company’s pipeline towards the clinic.”

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024

Retrieved on: 
Mercoledì, Maggio 8, 2024
Doctor of Philosophy, Cell, IL10, Pulmonary fibrosis, Cirrhosis, Liver, Doctor of Pharmacy, Society, Gene, Fibrosis, Macrophage, Lung, CARM, Therapy, Bleomycin, MASH, Medical imaging

PHILADELPHIA, May 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new data demonstrating preclinical proof of concept using engineered anti-fibrotic macrophages for the treatment of liver fibrosis. The data was presented in a poster session at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting on May 8, 2024, in Baltimore, MD.

Key Points: 
  • PHILADELPHIA, May 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new data demonstrating preclinical proof of concept using engineered anti-fibrotic macrophages for the treatment of liver fibrosis.
  • The data was presented in a poster session at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting on May 8, 2024, in Baltimore, MD.
  • "The data, from two independent models, demonstrate that engineered macrophages trafficked to fibrotic tissues, expressed genetically encoded disease-modifying payloads, and significantly reduced fibrosis in the liver.
  • In the presentation titled "Genetically Engineered Macrophage Cell Therapy Reverses Liver and Lung Fibrosis in Preclinical Models," Carisma presented preclinical proof-of-concept data for engineered macrophage cell therapy in liver fibrosis.

Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk

Retrieved on: 
Venerdì, Maggio 3, 2024
Mental Health, Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Obesity, NLRP3, Therapy, Novo Nordisk, Senior, Partnership, Trial of the century, Chronic kidney disease, Safety, MASH, Pharmacokinetics, Pharmaceutical industry

Ventus Therapeutics, Inc. , a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE™, to develop differentiated small molecule therapeutics, today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor licensed by Novo Nordisk in September 2022.

Key Points: 
  • Ventus Therapeutics, Inc. , a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE™, to develop differentiated small molecule therapeutics, today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor licensed by Novo Nordisk in September 2022.
  • “NLRP3 inhibitors have potential in a wide variety of cardiometabolic diseases, including obesity, metabolic dysfunction-associated steatohepatitis (MASH), and chronic kidney disease.
  • Since the beginning of our partnership with Ventus, we have seen additional evidence for the broad range of opportunities addressable by targeting NLRP3,” said Karin Conde-Knape, Ph.D., Senior Vice President of Global Drug Discovery at Novo Nordisk.
  • “This trial initiation marks the first stage in our NLRP3 inhibitor clinical program, and we are eager to be a key player in this expanding field.”
    The Phase 1 study is designed to fully explore the pharmacokinetics, pharmacodynamics, and safety of NNC6022-0001 across a broad range of doses in healthy volunteers.